Molecular Biosystems Inc. - Company Profile

BioCentury | Aug 13, 2001

Company News

Alliance Pharmaceutical, Mallinckrodt, Nycomed Amersham plc deal

...NAM’s Nycomed Amersham Imaging unit to develop and market ultrasound products, including Optison from ALLP’s Molecular Biosystems Inc....
...result, Molecular BioSystems will receive a cash payment from Mallinckrodt and royalties for two years. Prior, Molecular BioSystems...

BioCentury | Aug 13, 2001

Company News

Sonus, Nycomed Amersham deal

...NYE its interest in an ultrasound contrast patent license agreement with Chugai Pharmaceuticals Co. and Molecular Biosystems Inc....

BioCentury | Jan 22, 2001

Company News

Alliance, Sonus, Chugai deal

...SNUS granted Molecular Biosystems Inc. , a subsidiary of ALLP, and partner Chugai non-exclusive rights in Japan, South...
...partner Chugai non-exclusive rights in Japan, South Korea and Taiwan to certain SNUS patents covering Molecular Biosystems'...

BioCentury | Jan 8, 2001

Company News

Alliance, Molecular Biosystems deal

...price of $7.8125 (see BioCentury, Oct. 16, 2000). Alliance Pharmaceutical Corp. (ALLP), San Diego, Calif. Molecular Biosystems Inc....

BioCentury | Oct 16, 2000

Company News

Alliance, Molecular Biosystems deal

...Imagent ultrasound contrast agent (see BioCentury, Aug. 28). Alliance Pharmaceutical Corp. (ALLP), San Diego, Calif. Molecular Biosystems Inc....

BioCentury | Oct 16, 2000

Clinical News

EchoGen perflenapent ultrasound contrast agent regulatory update

...of patent infringement litigation, SNUS is eligible for royalties on ultrasound contrast agents sold by Molecular Biosystems Inc....

BioCentury | Oct 12, 2000

Company News

Alliance to acquire Molecular Biosystems

ALLP said it will acquire MBIO for 770,000 shares of ALLP stock, valuing MBIO at $10.2 million based on ALLP's Thursday close at $13.25. MBIO developed Optison , an intravenous ultrasound contrast agent on the market...

BioCentury | Oct 12, 2000

Company News

Sonus drops EchoGen, refocuses

...of patent infringement litigation, SNUS is eligible for royalties on ultrasound contrast agents sold by Molecular Biosystems...

BioCentury | Jun 12, 2000

Company News

Genta, Molecular Biosystems deal

...of antisense technology. MBIO will receive cash and GNTA stock. Genta Inc. (GNTA), Lexington, Mass. Molecular Biosystems Inc....

BioCentury | Jun 5, 2000

Company News

Molecular Biosystems licenses patents to Genta

MBIO granted exclusive and non-exclusive royalty-free licenses to GNTA on a portfolio of patents covering antisense technology for therapeutic and diagnostic use. GNTA will pay cash and GNTA stock. BC Staff...

Items per page: